Pioglitazone attenuates the detrimental effects of Advanced Glycation End-Products in the pancreatic beta cell line HIT-T15

Regulatory Peptides

Volumn 177, Issue 1-3, 2012, Pages 79-84

  Puddu, A ^a   Sanguineti, R ^a   Durante, A ^a   Viviani, G L ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Advanced Glycation End Products; Diabetes; Pancreatic beta cells; Pioglitazone

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CASPASE 3; GLUCOSE; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; PIOGLITAZONE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL PROTECTION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; INSULIN RELEASE; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CRICETINAE; CULTURE MEDIA; GLUCOSE; GLUTATHIONE; GLYCOSYLATION END PRODUCTS, ADVANCED; INSULIN; INSULIN-SECRETING CELLS; NF-KAPPA B; OXIDATION-REDUCTION; PHOSPHORYLATION; RECEPTORS, IMMUNOLOGIC; THIAZOLIDINEDIONES;

EID: 84862753221     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.05.089     Document Type: Article

References (41)

1. Bell D.S. Beta-cell rejuvenation with thiazolidinediones. Am J Med 2003, 115(Suppl. 8A):20S-23S.
2. Bell D.S. Beneficial effects resulting from thiazolidinediones for treatment of type 2 diabetes mellitus. Postgrad Med Spec No 2003, 35-44.
3. Campbell I.W., Mariz S. Beta-cell preservation with thiazolidinediones. Diabetes Res Clin Pract 2007, 76:163-176.
4. Zeender E., Maedler K., Bosco D., Berney T., Donath M.Y., Halban P.A. Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab 2004, 89:5059-5066.
5. Kawasaki F., Matsuda M., Kanda Y., Inoue H., Kaku K. Structural and functional analysis of pancreatic islets preserved by Pioglitazone in db/db mice. Am J Physiol Endocrinol Metab 2005, 288:E510-E518.
6. Ishida H., Takizawa M., Ozawa S., Nakamichi Y., Yamaguchi S., Katsuta H., Tanaka T., Maruyama M., Katahira H., Yoshimoto K., Itagaki E., Nagamatsu S. Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: possible protection of beta cells from oxidative stress. Metabolism 2004, 53:488-494.
7. Gumieniczek A., Hopkala H., Zabek A. Protective effects of a PPARgamma agonist Pioglitazone on anti-oxidative system in testis of diabetic rabbits. Pharmazie 2008, 63:377-378.
8. Collino M., Aragno M., Mastrocola R., Gallicchio M., Rosa A.C., Dianzani C., Danni O., Thiemermann C., Fantozzi R. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 2006, 530:70-80.
9. Gumieniczek A., Krzywdzinska M., Nowak M. Modulation of nitrosative/oxidative stress in the lung of hyperglycemic rabbits by two antidiabetics, Pioglitazone and repaglinide. Exp Lung Res 2009, 35:371-379.
10. Somi M.H., Hajipour B., Asl N.A., Estakhri R., Azar A.N., Zade M.N., Haghjou A.G., Vatankhah A.M. Pioglitazone attenuates ischemia/reperfusion-induced liver injury in rats. Transplant Proc 2009, 41:4105-4109.
11. Saitoh Y., Chun-ping C., Noma K., Ueno H., Mizuta M., Nakazato M. Pioglitazone attenuates fatty acid-induced oxidative stress and apoptosis in pancreatic beta-cells. Diabetes Obes Metab 2008, 10:564-573.
12. Bernardo A., Bianchi D., Magnaghi V., Minghetti L. Peroxisome proliferator-activated receptor-gamma agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells. J Neuropathol Exp Neurol 2009, 68:797-808.
13. Liu X., Luo D., Zheng M., Hao Y., Hou L., Zhang S. Effect of Pioglitazone on insulin resistance in fructose-drinking rats correlates with AGEs/RAGE inhibition and block of NADPH oxidase and NF kappa B activation. Eur J Pharmacol 2010, 629:153-158.
14. Ao C., Huo Y., Qi L., Xiong Z., Xue L., Qi Y. Pioglitazone suppresses the lipopolysaccharide-induced production of inflammatory factors in mouse macrophages by inactivating NF-kappaB. Cell Biol Int 2009, 34(7):723-730.
15. Wan H., Yuan Y., Qian A., Sun Y., Qiao M. Pioglitazone, a PPARgamma ligand, suppresses NFkappaB activation through inhibition of IkappaB kinase activation in cerulein-treated AR42J cells. Biomed Pharmacother 2008, 62:466-472.
16. Singh R., Barden A., Mori T., Beilin L. Advanced glycation end-products: a review. Diabetologia 2001, 44:129-146.
17. Ulrich P., Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001, 56:1-21.
18. Jakus V., Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res 2004, 53:131-142.
19. Bierhaus A., Nawroth P.P. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009, 52:2251-2263.
20. Wautier J.L., Guillausseau P.J. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001, 27:535-542.
21. Luciano Viviani G., Puddu A., Sacchi G., Garuti A., Storace D., Durante A., Monacelli F., Odetti P. Glycated fetal calf serum affects the viability of an insulin-secreting cell line in vitro. Metabolism 2008, 57:163-169.
22. Puddu A., Storace D., Odetti P., Viviani G.L. Advanced glycation end-products affect transcription factors regulating insulin gene expression. Biochem Biophys Res Commun 2010, 395:122-125.
23. Odetti P., Fogarty J., Sell D.R., Monnier V.M. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992, 41:153-159.
24. Misko T.P., Moore W.M., Kasten T.P., Nickols G.A., Corbett J.A., Tilton R.G., McDaniel M.L., Williamson J.R., Currie M.G. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993, 233:119-125.
25. Arenzana-Seisdedos F., Thompson J., Rodriguez M.S., Bachelerie F., Thomas D., Hay R.T. Inducible nuclear expression of newly synthesized I kappa B alpha negatively regulates DNA-binding and transcriptional activities of NF-kappa B. Mol Cell Biol 1995, 15:2689-2696.
26. Arenzana-Seisdedos F., Turpin P., Rodriguez M., Thomas D., Hay R.T., Virelizier J.L., Dargemont C. Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J Cell Sci 1997, 110(Pt 3):369-378.
27. Huang T.T., Kudo N., Yoshida M., Miyamoto S. A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. Proc Natl Acad Sci U S A 2000, 97:1014-1019.
28. Wittayalertpanya S., Chompootaweep S., Thaworn N. The pharmacokinetics of Pioglitazone in Thai healthy subjects. J Med Assoc Thai 2006, 89:2116-2122.
29. Wang A.P., Li X., Liu B.L., Zheng Y., Zheng C., Lin J., Huang G., Yan X., Peng J., Zhou Z.G. Inhibitory effects of thiazolidinedione upon cytokine-induced apoptosis in pancreatic beta-cell line. Zhonghua Yi Xue Za Zhi 2009, 89:1989-1993.
30. Li X., Wang A.P., Yan X., Huang G., Liu B.L., Zhou Z.G. Glitazones protects beta cell function from cytotoxic cytokines through PPAR gamma-dependent mechanisms. Nan Fang Yi Ke Da Xue Xue Bao 2010, 30:1530-1533.
31. Matsuda M., Kawasaki F., Inoue H., Kanda Y., Yamada K., Harada Y., Saito M., Eto M., Matsuki M., Kaku K. Possible contribution of adipocytokines on diabetic neuropathy. Diabetes Res Clin Pract 2004, 66(Suppl. 1):S121-S123.
32. Kanda Y., Shimoda M., Hamamoto S., Tawaramoto K., Kawasaki F., Hashiramoto M., Nakashima K., Matsuki M., Kaku K. Molecular mechanism by which Pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist. Am J Physiol Endocrinol Metab 2010, 298:E278-E286.
33. Lamontagne J., Pepin E., Peyot M.L., Joly E., Ruderman N.B., Poitout V., Madiraju S.R., Nolan C.J., Prentki M. Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic beta-cell at submaximal glucose concentrations. Endocrinology 2009, 150:3465-3474.
34. Tiedge M., Lortz S., Drinkgern J., Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 1997, 46:1733-1742.
35. Tiedge M., Lortz S., Munday R., Lenzen S. Complementary action of antioxidant enzymes in the protection of bioengineered insulin-producing RINm5F cells against the toxicity of reactive oxygen species. Diabetes 1998, 47:1578-1585.
36. Lu S.C. Regulation of glutathione synthesis. Curr Top Cell Regul 2000, 36:95-116.
37. Park E.Y., Cho I.J., Kim S.G. Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer. Cancer Res 2004, 64:3701-3713.
38. Puddu A., Storace D., Durante A., Odetti P., Viviani G.L. Glucagon-like peptide-1 counteracts the detrimental effects of Advanced Glycation End-Products in the pancreatic beta cell line HIT-T 15. Biochem Biophys Res Commun 2010, 398:462-466.
39. Zhang X., Dong F., Ren J., Driscoll M.J., Culver B. High dietary fat induces NADPH oxidase-associated oxidative stress and inflammation in rat cerebral cortex. Exp Neurol 2005, 191:318-325.
40. Rahbar S., Natarajan R., Yerneni K., Scott S., Gonzales N., Nadler J.L. Evidence that Pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 2000, 301:65-77.
41. Kanazawa I., Yamamoto M., Yamaguchi T., Sugimoto T. Effects of metformin and Pioglitazone on serum pentosidine levels in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2011, 119:362-365.